Indian Immunologicals launches its first set of virtual medical representatives
Indian Immunologicals Limited ( IIL ) the Hyderabad based subsidiary of National Dairy Development Board ( NDDB ) has been in the forefront of business process innovation . Propelling the digital ecosystem , IIL , through its division Human Biologicals Institute , launched its first set of virtual medical representatives , a pioneering alternative to facilitate physician ’ s interface in form of eMOz i . e . A virtual realm where e-reps can connect with doctors and foster digital relationship . eMOZ is a cutting edge and promising tool for information sharing . eMOz have inbuilt capabilities to provide constant update on specific needs of the physicians , thus fostering meaningful , tangible , and enduring gains . eMOz will enable complete stakeholder management on a virtual platform by providing detailed access to products and services . It will eventually be acquiring AI avatars of sales representatives to interact and assist physicians in one of its kind experiences .
Biotech startup CrisprBits raises 250,000 USD in pre-seed round
CrisprBits , one of the first Indian companies using CRISPR , a breakthrough geneediting technology , has raised 250,000 USD in Pre-seed funding from US-based VJ
Group . The funding will be used towards product development , team expansion and for research and development . Founded by Dr Vijay Chandru , Sunil Arora , Dr Rajeev Kohli , Bharat Jobanputra , and Aditya Sarda in 2020 , CrisprBits was started with a vision of developing high-quality healthcare solutions in diagnostics and gene editing that all Indians can afford . The company plans to extend its CRISPR-based diagnostics platform to point-ofcare detection of pathogens and antimicrobial resistance genes associated with hospitalacquired infections . CRISPR is used by bacteria to protect themselves from invading viruses and in the past few years , scientists have harnessed the power of CRISPR to develop therapeutics as well as other biotechnological products .
BioAsia 2023 : India ’ s ingenuity has been in releasing vaccines at large scale , says Dr Richard Hatchett
Dr Richard Hatchett , CEO , CEPI , UK in his plenary talk at the 20th edition of BioAsia – the marquee healthcare and life sciences event , organized by the Government of Telangana , spoke about the unique opportunity presented by India . Dr Hatchett said : “ India ’ s concentration of talent and capability particularly in development of Medicine and leadership in G20 position India to help the world transform how it respond in terms of future infectious diseases . Viruses aren ’ t waiting for us to prepare . Covid -9 was
8
BioVoiceNews | March 2023